ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up
The use of two medicines together (combination therapies) for previously [...]
The use of two medicines together (combination therapies) for previously [...]
Cancer Research UK has reported that over the past 6 [...]
Adjuvant therapy is medication that is given in addition to [...]
The latest findings from five studies presented at the ESMO [...]
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) [...]
Metastatic collecting duct carcinoma is an aggressive form of RCC, [...]
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
There is increasing interest in using treatment breaks to reduce [...]
Following expert clinical advice, the government is ending the requirement [...]
NHS England is about to start a large-scale trial of [...]